Are Options Indicating a Surge in Masimo Stock?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 03 2025
0mins
Should l Buy MASI?
Source: NASDAQ.COM
Masimo Corporation Stock Analysis: Investors should monitor Masimo Corporation (MASI) due to high implied volatility in its options market, particularly the Oct 17, 2025 $70.00 Call, indicating expectations of significant price movement. Analysts have recently increased earnings estimates, suggesting a positive outlook for the company.
Quantum Computing Developments: Quantum computing is rapidly advancing, with major tech companies like Microsoft, Google, and Amazon integrating it into their operations. Stock strategist Kevin Cook has identified key stocks that may lead in this emerging field, presenting an opportunity for investors to capitalize on the next technological revolution.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MASI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MASI
Wall Street analysts forecast MASI stock price to rise
6 Analyst Rating
4 Buy
2 Hold
0 Sell
Moderate Buy
Current: 175.400
Low
162.00
Averages
188.40
High
210.00
Current: 175.400
Low
162.00
Averages
188.40
High
210.00
About MASI
Masimo Corporation is a global medical technology company that develops and produces a wide range of monitoring technologies, including measurements, sensors, patient monitors, automation and connectivity solutions. The Company’s healthcare products and patient monitoring solutions generally incorporate a monitor or circuit board, proprietary single-patient use or reusable sensors, software and/or cables. It primarily sells its healthcare products to hospitals, emergency medical service providers, home care providers, physician offices, veterinarians, long-term care facilities. Its measurement technologies include Measure-through Motion and Low Perfusion pulse oximetry, known as Masimo Signal Extraction Technology (SET) pulse oximetry, and advanced rainbow Pulse CO-Oximetry parameters such as noninvasive hemoglobin (SpHb), alongside many other modalities, including brain function monitoring, hemodynamic monitoring, regional oximetry, capnography and gas monitoring, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Parkman Healthcare Partners Acquires 200,000 Shares in Masimo
- New Investment Position: Parkman Healthcare Partners initiated a new stake in Masimo by acquiring 200,000 shares in Q4 2026, valued at $26.01 million, indicating strong confidence in the company's growth potential.
- Surging Stock Price: Masimo's shares have surged 35% this year, primarily due to its agreement to be acquired for $180 per share in a deal valued at approximately $9.9 billion, which is expected to significantly enhance the company's market position in the medical technology sector.
- Market Competitiveness: As a leading provider of advanced noninvasive monitoring technologies, Masimo leverages proprietary signal extraction and multi-parameter monitoring platforms to improve patient outcomes and workflow efficiency, solidifying its competitive edge in a rapidly evolving healthcare market.
- Portfolio Diversification: The new stake aligns with major healthcare holdings like Boston Scientific and Dexcom, reflecting Parkman Healthcare Partners' strategic focus on companies with strong intellectual property and durable demand in the healthcare sector.
See More
Parkman Healthcare Partners Acquires Stake in Masimo Corporation
- New Investment Position: Parkman Healthcare Partners disclosed a new position in Masimo Corporation by acquiring 200,000 shares worth $26.01 million in Q4 2025, indicating strong confidence in the company's future prospects.
- Asset Allocation Strategy: This investment represents 2.48% of Parkman Healthcare Partners' $1.05 billion in reportable U.S. equity assets, reflecting a strategic focus on the high-growth medical technology sector.
- Market Performance Insight: As of last Friday, Masimo shares were priced at $175.49, up about 6% over the past year, although underperforming the S&P 500's 20% gain, yet the stock surged significantly after the acquisition announcement, highlighting positive market sentiment.
- Acquisition Impact: Masimo agreed to be acquired for $180 per share in a deal valued at approximately $9.9 billion, expected to close in the second half of the year, which will enhance its market position in patient monitoring while allowing it to operate as a standalone brand.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Launched: Halper Sadeh LLC is investigating Masimo Corporation for its sale to Danaher Corporation at $180 per share in cash, potentially violating federal securities laws and fiduciary duties to shareholders, which could impact shareholder rights and transaction terms.
- Shareholder Rights Protection: The firm encourages shareholders of Masimo, Arcellx, and Great Lakes to reach out to discuss their rights and options, indicating a commitment to safeguarding shareholder interests and potentially seeking higher consideration or additional disclosures through legal channels.
- Potential Financial Benefits: The investigation highlights that insiders may receive substantial financial benefits not available to ordinary shareholders, suggesting that transaction terms could limit superior competing offers, thereby affecting market competition and potential shareholder returns.
- Global Investor Support: Halper Sadeh LLC represents investors worldwide, focusing on combating securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors, demonstrating its expertise in protecting investor rights.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation: Halper Sadeh LLC is investigating Masimo Corporation for potential violations of federal securities laws related to its sale to Danaher Corporation for $180 per share in cash, which may affect shareholder rights and options.
- Shareholder Rights Protection: The firm is also examining the sale of Great Lakes Dredge & Dock Corporation to Saltchuk Resources, Inc. for $17 per share, which may harm shareholder interests, encouraging shareholders to understand their rights.
- Merger Transaction Review: The merger of VerifyMe, Inc. with Open World Ltd. is also under scrutiny, with Halper Sadeh LLC potentially seeking increased compensation and additional disclosures to protect investors' legal rights.
- Legal Fee Arrangement: The firm commits to handling cases on a contingent fee basis, meaning shareholders will not incur legal fees, aiming to provide risk-free legal support for affected investors.
See More
Investigation Alerts for Multiple Company Mergers
- Masimo Merger Investigation: Masimo Corporation is set to be acquired by Danaher Corporation for $180 per share, totaling $9.9 billion, with investigations focusing on whether the Masimo Board breached fiduciary duties by failing to ensure a fair process in the deal.
- IHS Towers Acquisition Review: IHS Towers will be acquired by MTN Group for $8.50 per share in an all-cash transaction valued at approximately $6.2 billion, with investigations examining whether the IHS Board failed to conduct a fair process, potentially impacting shareholder value.
- VerifyMe Merger Scrutiny: VerifyMe will be acquired by Open World, allowing shareholders to retain a 10% stake post-merger, with investigations looking into whether the VerifyMe Board ensured a fair process, which could affect shareholder interests.
- Great Lakes Acquisition Investigation: Great Lakes Dredge & Dock Corporation is being acquired by Saltchuk Resources for $17 per share, with a total transaction value of about $1.5 billion, and investigations are assessing whether the Board breached fiduciary duties by failing to ensure a fair process for shareholders.
See More
Exiting Danaher Position with 7% Loss
- Position Reduction: We sold 200 shares of Danaher at approximately $208 each on Thursday, resulting in a disappointing 7% loss on shares purchased between 2023 and 2025, reflecting our disillusionment with the company's future performance.
- Weak Growth: Despite our hopes for Danaher's bioprocessing business to recover post-COVID, its revenue growth has failed to achieve consistent high single-digit percentages, prompting us to clean up our portfolio to free up space for new opportunities.
- Lack of Confidence in Acquisitions: Our confidence in Danaher's recent acquisition strategy has waned, particularly as the acquisitions of Abcam and Aldevron did not drive performance as expected, deepening our pessimism regarding their acquisition of Masimo.
- Legal Risk Consideration: Given the longstanding legal battle between Apple and Masimo, which could pose additional risks for Danaher in the future, we are more inclined to seek alternative investment opportunities.
See More
Parkman Healthcare Partners Acquires 200,000 Shares in Masimo
- New Investment Position: Parkman Healthcare Partners initiated a new stake in Masimo by acquiring 200,000 shares in Q4 2026, valued at $26.01 million, indicating strong confidence in the company's growth potential.
- Surging Stock Price: Masimo's shares have surged 35% this year, primarily due to its agreement to be acquired for $180 per share in a deal valued at approximately $9.9 billion, which is expected to significantly enhance the company's market position in the medical technology sector.
- Market Competitiveness: As a leading provider of advanced noninvasive monitoring technologies, Masimo leverages proprietary signal extraction and multi-parameter monitoring platforms to improve patient outcomes and workflow efficiency, solidifying its competitive edge in a rapidly evolving healthcare market.
- Portfolio Diversification: The new stake aligns with major healthcare holdings like Boston Scientific and Dexcom, reflecting Parkman Healthcare Partners' strategic focus on companies with strong intellectual property and durable demand in the healthcare sector.
See More
Parkman Healthcare Partners Acquires Stake in Masimo Corporation
- New Investment Position: Parkman Healthcare Partners disclosed a new position in Masimo Corporation by acquiring 200,000 shares worth $26.01 million in Q4 2025, indicating strong confidence in the company's future prospects.
- Asset Allocation Strategy: This investment represents 2.48% of Parkman Healthcare Partners' $1.05 billion in reportable U.S. equity assets, reflecting a strategic focus on the high-growth medical technology sector.
- Market Performance Insight: As of last Friday, Masimo shares were priced at $175.49, up about 6% over the past year, although underperforming the S&P 500's 20% gain, yet the stock surged significantly after the acquisition announcement, highlighting positive market sentiment.
- Acquisition Impact: Masimo agreed to be acquired for $180 per share in a deal valued at approximately $9.9 billion, expected to close in the second half of the year, which will enhance its market position in patient monitoring while allowing it to operate as a standalone brand.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Launched: Halper Sadeh LLC is investigating Masimo Corporation for its sale to Danaher Corporation at $180 per share in cash, potentially violating federal securities laws and fiduciary duties to shareholders, which could impact shareholder rights and transaction terms.
- Shareholder Rights Protection: The firm encourages shareholders of Masimo, Arcellx, and Great Lakes to reach out to discuss their rights and options, indicating a commitment to safeguarding shareholder interests and potentially seeking higher consideration or additional disclosures through legal channels.
- Potential Financial Benefits: The investigation highlights that insiders may receive substantial financial benefits not available to ordinary shareholders, suggesting that transaction terms could limit superior competing offers, thereby affecting market competition and potential shareholder returns.
- Global Investor Support: Halper Sadeh LLC represents investors worldwide, focusing on combating securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors, demonstrating its expertise in protecting investor rights.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation: Halper Sadeh LLC is investigating Masimo Corporation for potential violations of federal securities laws related to its sale to Danaher Corporation for $180 per share in cash, which may affect shareholder rights and options.
- Shareholder Rights Protection: The firm is also examining the sale of Great Lakes Dredge & Dock Corporation to Saltchuk Resources, Inc. for $17 per share, which may harm shareholder interests, encouraging shareholders to understand their rights.
- Merger Transaction Review: The merger of VerifyMe, Inc. with Open World Ltd. is also under scrutiny, with Halper Sadeh LLC potentially seeking increased compensation and additional disclosures to protect investors' legal rights.
- Legal Fee Arrangement: The firm commits to handling cases on a contingent fee basis, meaning shareholders will not incur legal fees, aiming to provide risk-free legal support for affected investors.
See More
Investigation Alerts for Multiple Company Mergers
- Masimo Merger Investigation: Masimo Corporation is set to be acquired by Danaher Corporation for $180 per share, totaling $9.9 billion, with investigations focusing on whether the Masimo Board breached fiduciary duties by failing to ensure a fair process in the deal.
- IHS Towers Acquisition Review: IHS Towers will be acquired by MTN Group for $8.50 per share in an all-cash transaction valued at approximately $6.2 billion, with investigations examining whether the IHS Board failed to conduct a fair process, potentially impacting shareholder value.
- VerifyMe Merger Scrutiny: VerifyMe will be acquired by Open World, allowing shareholders to retain a 10% stake post-merger, with investigations looking into whether the VerifyMe Board ensured a fair process, which could affect shareholder interests.
- Great Lakes Acquisition Investigation: Great Lakes Dredge & Dock Corporation is being acquired by Saltchuk Resources for $17 per share, with a total transaction value of about $1.5 billion, and investigations are assessing whether the Board breached fiduciary duties by failing to ensure a fair process for shareholders.
See More
Exiting Danaher Position with 7% Loss
- Position Reduction: We sold 200 shares of Danaher at approximately $208 each on Thursday, resulting in a disappointing 7% loss on shares purchased between 2023 and 2025, reflecting our disillusionment with the company's future performance.
- Weak Growth: Despite our hopes for Danaher's bioprocessing business to recover post-COVID, its revenue growth has failed to achieve consistent high single-digit percentages, prompting us to clean up our portfolio to free up space for new opportunities.
- Lack of Confidence in Acquisitions: Our confidence in Danaher's recent acquisition strategy has waned, particularly as the acquisitions of Abcam and Aldevron did not drive performance as expected, deepening our pessimism regarding their acquisition of Masimo.
- Legal Risk Consideration: Given the longstanding legal battle between Apple and Masimo, which could pose additional risks for Danaher in the future, we are more inclined to seek alternative investment opportunities.
See More
